NCT06378567

Brief Summary

A home placement, randomized, double blind, placebo-controlled, study to determine the effect of dietary liquid shot beverage products on self-reported measures of sleep, stress and mood on generally healthy participants with current self-reported mild/moderate sleep difficulties (but not clinical insomnia) and mild/moderate stress.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
176

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Aug 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 17, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 22, 2024

Completed
4 months until next milestone

Study Start

First participant enrolled

August 5, 2024

Completed
27 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2024

Completed
Last Updated

April 1, 2025

Status Verified

August 1, 2024

Enrollment Period

27 days

First QC Date

April 17, 2024

Last Update Submit

March 25, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Sleep Disturbance

    Change in Patient-Reported Outcomes Measurement Information Systems (PROMIS) - Sleep disturbance 8A Scores range from 8-40, where lower scores indicate lower sleep disturbance

    Time points: Week 1, 2, 3 and 4

Secondary Outcomes (6)

  • Sleep Impairment

    Time points: Weeks 1, 2, 3, and 4

  • Insomnia Severity Scores range from 0-24, where lower scores indicate lower insomnia severity

    Time points: Weeks 1, 2, 3, and 4

  • Restorative Sleep Scores range from 0-100, where higher scores indicate better restorative sleep

    Time points: Weeks 1, 2, 3, and 4

  • Contentedness/Anxiety Scores range from 6-24, where lower scores indicate lower levels of state anxiety

    Time points: Weeks 1, 2, 3, and 4

  • Profile of Mood States (POMS 35 Item version)

    Time points: Weeks 1, 2, 3, and 4

  • +1 more secondary outcomes

Study Arms (3)

Placebo comparator

PLACEBO COMPARATOR

Investigational liquid shot beverage product: prototype 60ml product that does not contain study ingredients

Dietary Supplement: Dietary supplement liquid shot beverage products

Experimental Product 1

EXPERIMENTAL

Developmental liquid shot beverage product: prototype 60ml product that contains study ingredients

Dietary Supplement: Dietary supplement liquid shot beverage products

Experimental Product 2

EXPERIMENTAL

Developmental liquid shot beverage product: prototype 60ml product that contains study ingredients

Dietary Supplement: Dietary supplement liquid shot beverage products

Interventions

Participants will use their product as instructed for 3 of the 4 study weeks

Experimental Product 1Experimental Product 2Placebo comparator

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Generally healthy participants, between 18 and 55 years of age.
  • Participants who are not clinical insomniacs (as determined by a medical professional in the last 12 months, or who meets the ISQ criteria in screening).
  • Participants who are in good self-reported physical and mental health.
  • Participants with current self-reported mild/moderate sleep difficulties wishing to improve their sleep (as determined by an AIS score of 7 or more, but 14 or less).
  • Participants with current self-reported mild/moderate stress wishing to improve their stress level (as determined by a PSQ raw score of 38 or higher).
  • Participants that are willing to not use other new dietary supplements throughout the study but continue to use their normal dietary supplements (if any) as per their normal routine.
  • Participants who can provide written informed consent to participate in the study and will have agreed to abide by the study restrictions, requirements and protocol.
  • Participants must, in the opinion of the Principal Investigator (or designee), demonstrate the ability to comprehend the informed consent form (ICF), understand and comply with the requirements of the study, and be judged suitable for the study.
  • Participants must be available to complete the study.
  • Participants must be willing to abstain from alcohol after 6 pm each day.
  • Participants must consume less than 400 mgs of caffeine per day.
  • Participants must consume 7 servings or less of alcohol in a typical week

You may not qualify if:

  • Participants that are not US citizens or residents.
  • Participants that have a medical condition, including but not limited to heartbeat/rhythm irregularities, past heart attacks, been diagnosed with heart disease, seizure disorder, autoimmune disease, kidney disorder or impairment, chronic sinus condition, liver condition, blood clotting disorder, endocrine-related medical diagnosis (such as diabetes, thyroid, etc.), asthma/emphysema/COPD, serious health condition (i.e., cancer, etc.), blindness, insomnia, narcolepsy, anxiety, depression, hypertension, or deafness.
  • Participants that have a BMI outside the range of 18.5 to 35.
  • Participants that do not sleep during the night, do not work day-shift hours, or have other factors that impact their sleep schedule such as an inconsistent work schedule, or dealing with chronic pain or having a sleep disorder (such as Night Terrors, Narcolepsy, Insomnia, or Sleep Apnoea).
  • Participants that do not have any difficulty sleeping.
  • Participants that use recreational drugs or that are currently taking prescription medication (except for a contraceptive).
  • Participants that are pregnant, breastfeeding (or pumping/expressing) or intend to become pregnant within the next six months.
  • Participants that currently use cannabinoid products, smoke cigarettes or use any tobacco or nicotine products.
  • Participants that are allergic or sensitive to any of the product ingredients.
  • Participants that are currently or have participated in sleep-related studies or any product research studies in the last 30 days.
  • Participants that currently work (or who have an immediate family member who works) for a market research, marketing, advertising, public relations, pharmaceutical, food/beverage or tobacco company.
  • Participants that use sleep aids every night or multiple times a week.
  • Participants who are unwilling or unable to comply with the study requirements and restrictions including those outlined in the Participant Handbook.
  • Participants that are traveling over the next 4-6 weeks, to an extent where the time zone difference would impact their regular sleep schedule

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sago Atlanta - The Palisades Complex

Atlanta, Georgia, 30328, United States

Location

Study Officials

  • Michelle Niedziela, PhD

    HCD Research

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: Parallel Assignment
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 17, 2024

First Posted

April 22, 2024

Study Start

August 5, 2024

Primary Completion

September 1, 2024

Study Completion

September 1, 2024

Last Updated

April 1, 2025

Record last verified: 2024-08

Locations